In breast cancer, UBE3A appears to play conflicting roles and promotes and suppresses cancer progression by acting as a transcriptional co-activator for the estrogen receptor alpha, the progesterone receptor and the androgen receptor, and by ubiquitinating the estrogen receptor and androgen receptor and promoting their degradation [302]. Here, AR is linked to breast cancer.